160 results on '"Di Costanzo G.G."'
Search Results
2. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
3. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study
4. Prognostic impact of previous intraarterial treatment in patients with hcc treated with sorafenib
5. OC.12.4 PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB
6. Safety and Efficacy of Subcutaneous Hepatitis B Immunoglobulin After Liver Transplantation: An Open Single-Arm Prospective Study
7. SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study
8. Elevated CD4 +/CD25 + T-cell Frequency and Function During Hepatitis C Virus Recurrence After Liver Transplantation
9. AF.93 COVID-19 IN LIVER TRANSPLANT RECIPIENTS: AN ITALIAN CASE-CONTROL DOUBLE-CENTER STUDY
10. Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model
11. Adipopenia, among the nutritional parameters, is the one that best correlates with mortality in decompensated cirrhotic patients: results of a prospective study
12. P.04.14 HEPATOCELLULAR CARCINOMA AND SMOKING ARE INDEPENDENT RISK FACTORS FOR DEVELOPMENT OF DE-NOVO EXTRAHEPATIC TUMORS IN LIVER TRANSPLANT RECIPIENTS
13. OC.07.4 HCC RECURRENCE AFTER DAA TREATMENT IN HCV PATIENTS
14. HCC recurrence after DAA treatment in HCV patients
15. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: A pilot study
16. P.09.7: Mucosal GUT Microbiota Composition in Patients with HCV Infection, from Chronic Hepatitis to Hepatocellular Carcinoma
17. Effectiveness of percutaneous ethanol injection in relation to hepatocellular carcinoma size: A single centre experience
18. Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience
19. Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma
20. Efficacy and safety of percutaneous laser ablation therapy for treatment of large HCC
21. Sorafenib in clinical practice: Pooled analysis of two prospective observational studies in hepatocellular carcinoma (HCC)
22. Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania
23. Efficacy and Safety of Percutaneous Laser Ablation Therapy for Treatment of Large Hepatocellular Carcinoma
24. Early Evaluation of Alpha-Fetoprotein Response for Predicting Outcomes in Sorafenib Treated Patients May be Misleading
25. Safety and efficacy of sorafenib in stella study, a Multicenter, Observational, Phase IV Study In Italian Centers
26. P0369 : Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients
27. A rare cause of diuretic refractory ascites
28. No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy
29. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients
30. SAT-224 - Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience
31. SAT-088 - Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma
32. P.17.10 ADHERENCE TO TRIPLE THERAPY IN HCV
33. THU-094 - Efficacy and Safety of Percutaneous Laser Ablation Therapy for Treatment of Large Hepatocellular Carcinoma
34. THU-058 - Adherence to Guidelines in Field-Practice: Progetto Epatocarcinoma Campania
35. THU-059 - Early Evaluation of Alpha-Fetoprotein Response for Predicting Outcomes in Sorafenib Treated Patients May be Misleading
36. P.18.24 CIRCULATING SCCA-IgM COMPLEX IS ABLE TO MONITOR THE SUCCESS OF LOCO-REGIONAL THERAPY IN HCC PATIENTS
37. P.18.23 SCCA-IgM: A BIOMARKER TO MONITOR THE OUTCOME OF THERAPY WITH SORAFENIB IN ADVANCED HCC
38. F-43 Demographic, clinical and biochemical characteristics of hepatocellular carcinoma in southern Italy
39. T-50 Patients/doctors/nurses relationship after liver transplantation: a prospective study on patient's satisfaction
40. OC-14 Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma: a randomized controlled trial
41. T-30 Mortality for chronic liver disease and hepatocellular carcinoma in Italy and Europe over the last 40 years
42. P.08.2 SERUM LEVELS OF SCCA-IGM ARE RELATED TO THE EFFICACY OF HCC TREATMENTS
43. 629 SAFETY AND EFFECTIVENESS OF TREATMENT WITH SORAFENIB IN ELDERLY CIRRHOTIC PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMA
44. 414 PEG-INTERFERON PLUS RIBAVIRIN TREATMENT DOES NOT IMPROVE RECURRENCE AFTER RESECTION OR ABLATION OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS: A CASE-CONTROL STUDY
45. 660 FACTORS PREDICTIVE FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIB
46. P.1.1: PREDICTIVE FACTORS FOR TUMOR CONTROL AMONG HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH SORAFENIB
47. OC.10.1: RADIOFREQUENCY ABLATION VERSUS LASER ABLATION FOR THE TREATMENT OF SMALL HEPATOCELLULAR CARCINOMA: A RANDOMIZED CONTROLLED TRIAL
48. P.1.66: SAFETY AND EFFECTIVENESS OF TREATMENT WITH SORAFENIB IN ELDERLY CIRRHOTIC PATIENTS AFFECTED BY ADVANCED HEPATOCELLULAR CARCINOMA
49. P.1.97: SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA: EFFECTIVENESS AND IMPACT OF ADVERSE EFFECTS IN DAILY CLINICAL PRACTICE
50. T-40 Rebleeding does not affect prognosis of cirrhotic patients with advanced hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.